Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Metabolism-Related Features Identify the Combination Metformin Plus NAMPT Inhibitors As a Selective Treatment Strategy in Acute Myeloid Leukemia

Isabel Weinhaeuser, Diego Pereira-Martins, Dominique Sternadt, Emmanuel F Griessinger, Douglas RA Silveira, Juan L Coelho-Silva, Antonio Bruno Alves-Silva, Ayşegül Erdem, Bruno Koza Lino Duarte, Lynn Quek, Fabiola Traina, Sara Teresinha Olalla Saad, Jacobien R Hilberink, Emanuele Ammatuna, Eduardo Magalhães Rego, Geert A. Huls, Antonio R Lucena-Araujo, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 294.

https://doi.org/10.1182/blood-2023-186061

Published: 2023

Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Blood (2023) 142 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2023-184851

Published: 2023

Journal Articles

Clonal Hematopoiesis Is Common in Long-Term Survivors of Pediatric Hematopoietic Cell Transplantation, Including Umbilical Cord Blood Transplantation

Konradin F. Müskens, Maaike G.J.M. van Bergen, Aniek O. de Graaf, Nienke Wieringa, Brigit M. te Pas, Anne P.J. de Pagter, Joëll E. Bense, Arjan C. Lankester, Leontien C.M. Kremer, Joop H. Jansen, Geert A. Huls, Stefan Nierkens, Caroline A. Lindemans, Mirjam E. Belderbos

Blood (2023) 142 (Supplement 1): 2697.

https://doi.org/10.1182/blood-2023-185985

Published: 2023

Journal Articles

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Hilde T Van Der Galien, Hilde AM Kooistra, Robby Kibbelaar, Nic JGM Veeger, Marcel Nijland, Geert A. Huls, Tom Van Meerten, Rozemarijn S Van Rijn

Blood (2023) 142 (Supplement 1): 444.

https://doi.org/10.1182/blood-2023-185993

Published: 2023

Journal Articles

Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

Miranda van der Lee, Tanja van Achtenberg, Annet Brouwers-Vos, Monique van der Vleuten, Wendy Kappers, Gijs Verheijden, Geert A. Huls, Glenn van Wigcheren, Ruud Ubink, Aloys Sesink, Alyson MacInnes, Jan Jacob Schuringa, Wim Dokter

Blood (2023) 142 (Supplement 1): 2795.

https://doi.org/10.1182/blood-2023-177622

Published: 2023

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Thomas Pabst, Mojca Jongen-Lavrencic, Steffen Boettcher, Geert A. Huls, David C. de Leeuw, Philippe Legenne, Mariola Dymkowska, Christiane Andrieu, Oliver Schönborn-Kellenberger, Paul G. Baverel, Zita Arany, Elena Fernandez, Anne Goubier, Vladimir Kirkin, Nicolas Leupin, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2023-173353

Published: 2023

Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Blood (2011) 118 (21): 3841.

https://doi.org/10.1182/blood.V118.21.3841.3841

Published: 2011

Journal Articles

Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34 + Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML

Carolien M Woolthuis, Hendrik JM de Jonge, Annet Z Vos, Andre B Mulder, MD, Eva van den Berg, P.M. Kluin, MD, PhD, Karen van der Weide, Evelina S. De Bont, MD, PhD, Geert A Huls, MD, PhD, Edo Vellenga, MD, PhD, Jan J. Schuringa, PhD

Blood (2010) 116 (21): 952.

https://doi.org/10.1182/blood.V116.21.952.952

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation Induces a Phenotypical Shift From CMP to GMP Progenitors, Reduces Clonogenic Potential and Enhances in Vitro and In Vivo Cycling Activity Defined by 18 f-FLT PET Scan.

Carolien M. Woolthuis, Ali Agool, Annet Z. Vos, Riemert H.J.A. Slart, MD, PhD, Geert A. Huls, MD, PhD, W. Martin Smid, MD, PhD, Jan Jacob Schuringa, PhD, Edo Vellenga, MD, PhD

Blood (2009) 114 (22): 4473.

https://doi.org/10.1182/blood.V114.22.4473.4473

Published: 2009

Journal Articles

Distinct Gene Expression Profiling in AML in Elderly Versus Younger Patients

Henk-Marijn de Jonge, Evelina S de Bont, Peter Valk, Jan Jacob Schuringa, Marcel P Kies, Carolien M. Woolthuis, Ruud Delwel, Edo Vellenga, B. Lowenberg, Geert A Huls

Blood (2008) 112 (11): 2546.

https://doi.org/10.1182/blood.V112.11.2546.2546

Published: 2008

NARROW

Metabolism-Related Features Identify the Combination Metformin Plus NAMPT Inhibitors As a Selective Treatment Strategy in Acute Myeloid Leukemia

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Clonal Hematopoiesis Is Common in Long-Term Survivors of Pediatric Hematopoietic Cell Transplantation, Including Umbilical Cord Blood Transplantation

Patients with Relapsed Large B-Cell Lymphoma after 12 Months Have a Similarly Poor Prognosis As Patients with a Relapse before 12 Months

Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34 + Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML

Autologous Stem Cell Transplantation Induces a Phenotypical Shift From CMP to GMP Progenitors, Reduces Clonogenic Potential and Enhances in Vitro and In Vivo Cycling Activity Defined by 18 f-FLT PET Scan.

Distinct Gene Expression Profiling in AML in Elderly Versus Younger Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only